The page outlines BaraPharm’s three business pillars—platform, partnerships (BMS), and brands—and introduces its in-house brands, including OurPharm, Cheonhyedang, Noesin, and Revicle.
The page confirms BaraPharm’s final offering price of 16,400 won, a total offering amount of about 292 billion won, and plans for Kosdaq listing on November 11, focusing on AI, global, and production investments.
The page reports BaraPharm’s Q3 operating profit of 23 billion won, surpassing half-year levels, with cumulative sales of 1.185 trillion won in three quarters, exceeding last year’s annual total.
The page introduces BaraPharm’s vision, subsidiaries, and history as a healthcare platform expanding from pharmacies into AI, K-beauty, and in-house brands.
The page provides contact details for inquiries about partnerships, investments, media, and recruitment at BaraPharm’s headquarters in Seoul’s Dongjak-gu.
The page describes BaraPharm’s expansion of the healthcare ecosystem through pharmacy networks, covering pharmaceutical ordering, AI pharmacy management, K-beauty, and in-house brands.